National Register for Adults with Moderate to Severe Atopic Dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect clinical history and treatment data from adults suffering from moderate to severe atopic dermatitis (AD). It focuses on understanding the prevalence and characteristics of AD in adulthood, including cases that begin in adulthood or persist from childhood. The study will gather epidemiological and clinical data to help establish diagnostic criteria and improve treatment pathways for patients with adult-onset AD. By creating a national register, the study seeks to enhance the understanding of this condition and its impact on patients' quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18 years
2. Signature of informed consent
3. Diagnosis of moderate and/or severe DA by a dermatologist specialist defined on the basis of following criteria (10):

   * EASI 16
   * EASI \<16 but with at least one of the following conditions:

     1. location in at least one of the following "critical" locations: face, hands, genitals
     2. QID \> 10
     3. VAS itching \> 7
     4. VAS sleep \> 7

Exclusion Criteria:

1. Patient unable to provide informed consent prior to any collection procedures data on the study;
2. unable to complete the procedures required for the study;
3. a patient already participating in another follow-up register of the same disease.

Where it's running

• ASST Spedali Civili di Brescia
  Brescia, Brescia, Italy Recruiting

Study contacts

• Principal investigator: Piergiacomo MD Calzavara Pinton — Asst Degli Spedali Civili Di Brescia
• Study coordinator: Piergiacomo MD Calzavara Pinton
• Email: piergiacomo.calzavarapinton@unibs.it
• Phone: 0303995305

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

• ADBest TREAT Registry for adults with atopic dermatitis

  A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT07904546

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis

  This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.

  Recruiting Phase 1 QuantX Biosciences US Inc. · Shanghai, Shanghai Municipality · NCT07800104

• Tilrekimig for moderate-to-severe eczema in teens and adults

  A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.

  Recruiting at 31 sites Phase 3 Pfizer · Birmingham, Alabama and 49 other locations · NCT07783425

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.